Jiangsu Hengrui Medicine
600276.SS
#480
Rank
NZ$72.81 B
Marketcap
$11.42
Share price
-1.82%
Change (1 day)
1.91%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Jiangsu Hengrui Medicine (600276.SS) - P/B ratio

P/B ratio as of November 2024 : 6.89

According to Jiangsu Hengrui Medicine 's latest financial reports the company has a price-to-book ratio of 11.9672.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Jiangsu Hengrui Medicine - P/B ratio (from 2001 to 2024)

P/B ratio by year

Year P/B ratio Change
2024-12-31N/A-100%
2023-12-317.0010.68%
2022-12-316.33-30.61%
2021-12-319.12-52.76%
2020-12-3119.324.36%
2019-12-3115.559.24%
2018-12-319.75-19.7%
2017-12-3112.146.35%
2016-12-318.29-10.6%
2015-12-319.2834.21%
2014-12-316.91-10.93%
2013-12-317.7613.49%
2012-12-316.84-9.17%
2011-12-317.53-41.38%
2010-12-3112.85.05%
2009-12-3112.224.27%
2008-12-319.84-33.32%
2007-12-3114.874.66%
2006-12-318.45148.87%
2005-12-313.406.54%
2004-12-313.1934.53%
2003-12-312.37-25.07%
2002-12-313.16